| UPDATE ON RETINOPATHY OF PREMATURITY |
|
| Year : 2022 | Volume
: 36
| Issue : 3 | Page : 260-269 |
|
|
Anti-vascular endothelial growth factor therapy in retinopathy of prematurity: An updated literature review
Asma K Alzuabi1, Ola M Alshammari2, Abdullah N Almousa3, Marwan A Abouammoh3
1 Department of Ophthalmology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
2 Department of Medical Education, King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia
3 Department of Ophthalmology, College of Medicine, King Saud University, Riyadh, Saudi Arabia
Correspondence Address:
Prof. Marwan A Abouammoh
Department of Ophthalmology, College of Medicine, King Saud University, P.O. Box 245, Riyadh 11411
Saudi Arabia
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/sjopt.sjopt_12_22
|
|
|
Laser photocoagulation can still be considered the gold standard for treatment for retinopathy of prematurity (ROP). However, anti-vascular endothelial growth factor (anti-VEGF) therapy has increasingly become an important option that plays a significant role in the treatment of ROP. Major clinical trials have been published regarding the anti-VEGF use in ROP, along with multiple other studies looking into the different agents, doses, techniques, and possible complications. Anti-VEGF therapies can be considered as a safe and effective option for managing ROP. More longitudinal randomized clinical trials are necessary to evaluate the preferred treatment agent, the appropriate dose, best follow-up protocol, and the long-term ocular and systemic outcomes following treatment.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
